Trial-access debate
Do now
Argue a position on who should get access to experimental cancer drugs through clinical trials and right-to-try laws.
- Hand in
- One-sentence final stance plus the patient-facing reason you would give for your position.
- Where
- Turn this in at the drop folder with your district Microsoft sign-in, or hand it to Mr. Mendoza in class. Both count as submitted. Doing the activity in myPLTW does not.
You get two school days for every day you were absent, so this deadline moves with you.
A patient with stage IV and months to live wants a drug that has passed only Phase I testing. Should the oncologist, the drug maker, the insurer, or the patient get the final say?
Argue a position on who should get access to experimental drugs through clinical trials and right-to-try laws.
- • You'll be able to state who controls access to experimental treatments and why.
- • You'll be able to defend a position using clinical-trial evidence and counterargument.
- In one sentence, what is a clinical trial for: what does it test before a drug reaches patients?
- Name one reason a drug maker might refuse to give a dying patient an unproven drug, even when the law allows it.
- 1Read the two-page trial-access briefing in the PLTW course shell and highlight one fact for and one against expanded early access.
- 2Pick a stakeholder role: patient, oncologist, drug maker, or insurer, and write your opening claim in one sentence.
- 3List two pieces of evidence that support your claim using the terms clinical trial and .
- 4Trade claims with a partner role and write one respectful rebuttal to their strongest point.
- 5Vote on the class position and record your final stance plus the reason you would give a patient.
What did this day actually feel like?
Trial-access debate
ETHICS DAY Should a dying patient get an unproven drug? Compassionate access against the fact that if everyone gets it outside the trial, the trial never finishes and nobody learns whether it works.
The cruel part is that both positions are trying to save lives.
Turned in: exit ticket → Exit Tickets folder
Fiction. There is no such student. The lessons, labs and dates are the real planned course; the student, the classmates and the conversations are invented.
The same day, drawn.
Should a dying patient get an unproven drug? Compassionate access against the fact that if everyone gets it outside the trial, the trial never finishes and nobody learns whether it works.
ME
Both sides of this are trying to save lives. That is what makes it cruel.
Fiction. There is no such student. The lessons, labs and dates are the real planned course; the student, the classmates and the conversations are invented.
🛠 Get unstuck · pick your level
🔑 Today's words · 5
Tap a word in the lesson for a plain meaning and one example. Recycled into next week's Do-Now.
Do the work · 80-minute blockfirst 5 min = hook▸
💡 Big idea: Clinical trials gate access to unproven drugs so that a whole population is not exposed to a treatment before its risks are known, which forces hard trade-offs between one patient's autonomy and everyone else's .
- 0-8Silent read of trial-access briefing; highlight one pro, one con
- 8-15Choose stakeholder role; draft opening claim sentence
- 15-30Build evidence list (2 facts using required vocabulary)
- 30-50Pair debate: swap claims, write rebuttal
- 50-65Class vote and full-group discussion of strongest arguments
- 65-80Write final stance + patient-facing reason; exit ticket
- • Every approved drug began as an experiment someone had to decide was worth the risk.
- • Today you will step into that decision from four different stakeholder angles.
- • Your job is to argue a defensible position, not to find the right answer, because there may not be one.
- • By the end you will have practiced the claim-evidence-rebuttal structure you will use on the WebXam.
- • Clinical trials test and efficacy before a drug reaches the market.
- • Right-to-try laws allow terminal patients access outside normal trial pathways.
- • Expanded access decisions involve medical, ethical, and economic stakeholders.
Biopsy, imaging, staging, chemo, radiation, targeted therapy, response, side effects. · Trial-access debate
Day 1 of this lesson. Open this exact section in myPLTW (find it in Clever, Microsoft sign-in), then do the work below.
Do this: Open the trial-access debate activity in myPLTW for Unit 3, Lesson 3.4 Building a Better Treatment, Activity 3.4.3 Clinical Trials (open vs blind), and review the CER rubric.
Mark the trial-access debate entry complete and attach your exit ticket.
-launch morphology benchmarks should be green; this debate opens the cancer-treatment unit.
Written final stance and rebuttal visible as a tracker evidence item.
The official PLTW activity stays inside myPLTW. If myPLTW will not open, use F1 and E1-E3 on this page to complete today's local evidence decision, then make up the official activity when access returns. Turn this in at the drop folder with your district Microsoft sign-in, or hand it to Mr. Mendoza in class. Both count as submitted. Doing the activity in myPLTW does not.
Check things off as you work, then submit. This tells Mr. Mendoza how you're doing so he can help the class. It does not replace turning in your producible through the submission route shown below.
Use the code Mr. Mendoza gave you, not your name. Saved on this device.
Biopsy, imaging, staging, chemo, radiation, targeted therapy, response, side effects. · Trial-access debate
Open the trial-access debate activity in myPLTW for Unit 3, Lesson 3.4 Building a Better Treatment, Activity 3.4.3 Clinical Trials (open vs blind), and review the CER rubric.
-launch morphology benchmarks should be green; this debate opens the cancer-treatment unit.
This is how Mr. Mendoza sees the class keeping pace with PLTW. Be honest, it only helps if it is accurate.
🎯 Argue a position on who should get access to experimental drugs through clinical trials and right-to-try laws.
- Read the two-page trial-access briefing in the PLTW course shell and highlight one fact for and one against expanded early access.
- Pick a stakeholder role: patient, oncologist, drug maker, or insurer, and write your opening claim in one sentence.
- List two pieces of evidence that support your claim using the terms clinical trial and .
- Trade claims with a partner role and write one respectful rebuttal to their strongest point.
- Vote on the class position and record your final stance plus the reason you would give a patient.
Exit ticket: One-sentence final stance plus the patient-facing reason you would give for your position.
Turn this in at the drop folder with your district Microsoft sign-in, or hand it to Mr. Mendoza in class. Both count as submitted. Doing the activity in myPLTW does not. Use the checklist just below and upload by 11:29 PM for full credit. Absent with an excused absence? You get two school days for every day you were absent, so this deadline moves with you.
| Task | Who |
|---|---|
| Read the two-page trial-access briefing in the PLTW course shell and highlight one fact for and one against expanded early access. | _______ |
| Pick a stakeholder role: patient, oncologist, drug maker, or insurer, and write your opening claim in one sentence. | _______ |
| List two pieces of evidence that support your claim using the terms clinical trial and . | _______ |
| Trade claims with a partner role and write one respectful rebuttal to their strongest point. | _______ |
| Vote on the class position and record your final stance plus the reason you would give a patient. | _______ |
Working solo? Put your own name in "Who" for every row.
- You'll be able to state who controls access to experimental treatments and why.
- You'll be able to defend a position using clinical-trial evidence and counterargument.
- 1Do thisArgue a position on who should get access to experimental cancer drugs through clinical trials and right-to-try laws.
- 2Use this resource
- 3Submit thisExit ticket: One-sentence final stance plus the patient-facing reason you would give for your position.
- 4Submit it here
- 1Open the drop folder.
- 2Sign in with your district Microsoft account, not a personal one.
- 3Upload the file, named Lastname_Firstname__Assignment Title.
- 4Your own upload panel says Uploaded with a green check: that is your receipt.
Turn this in at the drop folder with your district Microsoft sign-in, or hand it to Mr. Mendoza in class. Both count as submitted. Doing the activity in myPLTW does not. Genetics of Disease (Medical Interventions) › Biopsy, imaging, staging, chemo, radiation, targeted therapy, response, side effects. › Exit ticketOpen the drop folder
Learn it · deck, reading, and vocabulary▸
The deck carries the prior idea forward, lets you inspect an analogy, maps the rule to biology, and ends with the same evidence decision and exit ticket used on this page.
Generated from this lesson's canonical data with a red-team citation check.
cells lose their normal shape and break through boundaries, so a pathologist can read invasion and disorganization on a slide to judge whether a can metastasize and how dangerous it is.
Clinical trials gate access to unproven drugs so that a whole population is not exposed to a treatment before its risks are known, which forces hard trade-offs between one patient's autonomy and everyone else's .
A pilot uses a preflight checklist before the aircraft moves.
- Which checks happen before action?
- Which hazard does each check control?
- What happens if a familiar step is skipped?
A routine works when each action controls a named hazard before exposure begins.
A laboratory hazard can change during a procedure, so students must keep monitoring conditions after the checklist.
- • Preflight checks map to PPE and setup.
- • Aircraft hazards map to chemical, biological, heat, or sharps hazards.
- • Go or no-go maps to the pre-lab readiness decision.
Driving question: A patient with stage IV and months to live wants a drug that has passed only Phase I testing. Should the oncologist, the drug maker, the insurer, or the patient get the final say?
What you already know: cells lose their normal shape and break through boundaries, so a pathologist can read invasion and disorganization on a slide to judge whether a can metastasize and how dangerous it is.
New idea: Clinical trials gate access to unproven drugs so that a whole population is not exposed to a treatment before its risks are known, which forces hard trade-offs between one patient's autonomy and everyone else's .
Visual or model: F1. F1. A lesson illustration or teaching diagram for Trial-access debate. Use it with E1-E3; it is a model or context image, not experimental or patient data. What to notice: Trace the labeled testing, treatment, or biological process and identify where evidence limits the decision.
- Observe or measure the relevant feature in Trial-access debate.
- Organize the observation with a stable evidence ID.
- Apply this rule: A routine works when each action controls a named hazard before exposure begins.
- Choose the option the evidence supports and state the limit of the conclusion.
Real biomedical example: A patient with stage IV and months to live wants a drug that has passed only Phase I testing. Should the oncologist, the drug maker, the insurer, or the patient get the final say?
What the evidence supports: E1-E3 and F1 support the daily take-home when the response meets the stated success criteria.
What it cannot prove: The package does not support claims beyond this lesson's or any real patient diagnosis.
- • : A medical procedure that removes a small sample of from the body so it can be examined under a microscope for disease such as .
- • staging: Classifying how far a has grown and spread, which guides treatment choices and predicts likely outcomes.
- • : Treatment that uses powerful drugs to kill rapidly dividing cells throughout the body, though it can also harm some fast-growing healthy cells.
- • radiation: Energy that travels as waves or particles; in medicine it can image inside the body or destroy harmful cells like .
- • : A treatment that attacks specific molecules cancer cells rely on, harming those cells while sparing more healthy cells than older .
- • : Programmed, controlled cell death that the body uses on purpose, including to clear the seam between two tissues during .
- • : An unintended effect of a medicine or treatment that happens in addition to its intended benefit, ranging from mild to serious.
Use it now: Choose one decision option. Cite E1 and E3, then explain how the rule connects the evidence to your choice.
Go further, optional: The source links below are optional enrichment. Every fact required for today's local evidence decision appears in this lesson package.
Clinical trials test and efficacy before a drug reaches the market.
Limit: E1 supplies context or an observation; it does not by itself establish the explanation.
Clinical trials gate access to unproven drugs so that a whole population is not exposed to a treatment before its risks are known, which forces hard trade-offs between one patient's autonomy and everyone else's .
Limit: E2 is a teaching statement or comparison and must be checked against the task evidence.
You'll be able to state who controls access to experimental treatments and why.
Limit: E3 supports only the result or product criterion named here; it cannot justify a broader clinical or causal claim.
PLTW-GEND-2026-11-10 · Simulated classroom evidence scenario
Your role: medical interventions team member
Decision: Your team must decide what the evidence from Trial-access debate supports before submitting the exit response named on the lesson page.
- • Select the option best supported by E1-E3.
- • Select a reasonable alternative and name the evidence it would require.
- • Delay the claim because the evidence does not distinguish the options.
Response: State one choice, cite at least two evidence IDs, explain the rule that connects them, and add one limitation. Submit it as the exit response.
Claim ceiling: The supplied lesson evidence can support an observation, pattern, classroom mechanism, or next-step decision about Trial-access debate. It cannot by itself prove causation, establish a real clinical diagnosis, or justify action outside this classroom task.
Reason for review: Your team must decide what the evidence from Trial-access debate supports before submitting the exit response named on the lesson page.
Context: Clinical trials protect the many by slowing access for the few, so every access decision trades one person's hope against everyone's .
- • T1: Read the two-page trial-access briefing in the PLTW course shell and highlight one fact for and one against expanded early access.
- • T2: Pick a stakeholder role: patient, oncologist, drug maker, or insurer, and write your opening claim in one sentence.
- • T3: List two pieces of evidence that support your claim using the terms clinical trial and .
- • T4: Trade claims with a partner role and write one respectful rebuttal to their strongest point.
- • T5: Vote on the class position and record your final stance plus the reason you would give a patient.
- • E1: Clinical trials test and efficacy before a drug reaches the market.
- • E2: Clinical trials gate access to unproven drugs so that a whole population is not exposed to a treatment before its risks are known, which forces hard trade-offs between one patient's autonomy and everyone else's .
- • E3: You'll be able to state who controls access to experimental treatments and why.
Measurements: Use only the measurements, units, graph, or counts supplied in today's task. No additional patient measurement is implied.
Figure finding: Teaching diagram for Trial-access debate. Trace the labeled testing, treatment, or biological process and identify where evidence limits the decision. This is a teaching model, not patient or experimental data.
Uncertainty: This is a composite classroom scenario. Missing history, measurements, or confirmation tests remain unknown and limit the conclusion.
= final volume / sample volume. New concentration = starting concentration / dilution factor.
Mix 1 mL of sample to a final volume of 10 mL. The is 10. A 100 mg/mL starting sample becomes 10 mg/mL.
Use the same volume units before dividing. Concentration keeps its original concentration unit.
Apply the same setup to one supplied dilution or dose. Show the factor, new value, units, and a reasonableness check.
Students often think Students assume that if a patient is dying anyway, there is no real downside to letting them try any experimental drug.. The trap: That skips the fact that an unproven drug can cause a faster, more painful death or use up the patient's last good weeks, and a bad early result can also shut down the trial for the thousands of patients waiting behind them, so the choice is never risk-free.
Parallel case (not today's prompt): A 12-year-old is the only close tissue match to donate a kidney to a sibling in kidney failure. The child says yes, but a minor cannot legally give full informed consent. Should the parents, the transplant surgeon, a hospital ethics committee, or the child have the final say on whether the donation happens?\n\nClaim: A hospital ethics committee, not the parents or the surgeon alone, should have the final say on whether a minor donates a kidney to a sibling, with the child given a real chance to refuse.\n\nEvidence: Living kidney donation is a surgery a healthy person does not medically need, and it carries real risks such as bleeding, infection, and the loss of one of two working kidneys for life. A 12-year-old cannot legally give informed consent, so someone else must decide for them. Parents have a clear interest in saving the sick child, which can pull them toward saying yes even when it is not in the donor child's best interest. For this reason, most transplant centers require a separate donor advocate and review by an independent ethics committee before a minor is allowed to donate, and courts have stepped in when a family and a hospital disagreed.\n\nReasoning: The person facing the risk of surgery is the donor child, but that child cannot legally weigh those risks alone, so the decision has to be shared. Handing the final say to the parents alone creates a conflict of interest, because they are also trying to save their other child, and handing it to the surgeon alone puts one person in charge of a life-altering choice for a healthy patient. An independent ethics committee is built to check exactly this kind of pressure: it can confirm the medical facts, protect the donor child's right to say no, and make sure the decision serves the donor and not only the sibling in need. That is why the committee, with the child's voice included, should hold the final say.
This model shows the level of evidence and organization needed to complete: Models the exact CER deliverable (Claim, Evidence, Reasoning) on a parallel bioethics access case so students can copy the structure and depth, not the answer: a single-sentence claim naming who should decide, evidence drawn from how the medical system actually handles the case, and reasoning that ties the evidence back to the claim.
- Name the prompt or task.
- Answer it directly with the key evidence.
- Check that the response matches the requested format.
Keep the structure. Replace the question, facts, measurements, and evidence. Then recheck units, vocabulary, and whether the conclusion goes beyond the evidence.
Also due today: Record the class vote and your final stance, and submit the exit ticket to the class site before leaving class.
- CER:
- Claim, Evidence, Reasoning: make a claim, back it with evidence, explain your reasoning.
- SOP:
- Standard Operating Procedure, the exact steps to follow (especially in a lab).
- Tracker:
- Your PLTW progress log where you record completed evidence.
- myPLTW:
- The PLTW course site where you do the online activities. Find it in Clever with your Microsoft sign-in, right next to Schoology.
Tap the speaker to hear a term. Add two of these to your notebook glossary with a definition and an example in your own words.
Pick just 2 or 3 words from today and make them yours: write what each one means in your own words, name the context clue or evidence that helped, then give one example from what you actually did in Trial-access debate. Try your own words first; the glossary is there if you get stuck. This is voluntary and counts as extra credit, so keep it short.
Saved on this device. Show Mr. Mendoza or add these to your notebook glossary to claim the extra credit.
Classroom documents for this lesson are posted in Schoology. Open Clever, then Schoology, and find each one by the name shown on its card.
Open this when the class reaches this activity and use it to complete the required lesson artifact.
Placement rationale
Matched treatment and therapeutic choices by path:Medical-Interventions/Unit-3_How-to-Conquer-Cancer/3.3_Treating-Cancer; keywords:, radiation, cancer. Score 146. Visibility: student-schoology (student-facing resource; link through Schoology rather than local path).
Use this if you were absent, got stuck, or need another pass before you submit the lesson artifact.
Placement rationale
Matched treatment and therapeutic choices by path:Medical-Interventions/Unit-3_How-to-Conquer-Cancer/3.4_Building-a-Better-Cancer-Treatment; keywords:treatment, cancer. Score 142. Visibility: student-schoology (student-facing resource; link through Schoology rather than local path).
How to get there: open Clever and sign in with your Microsoft (district) account. Both myPLTW and Schoology are in Clever. Do the activity in myPLTW. Turn the work in on this site or hand it to Mr. Mendoza, because that is the step that counts as submitted. Schoology only shows your report-card grade later.
Check yourself · commit, then reveal▸
Claim ceiling for this check: The supplied lesson evidence can support an observation, pattern, classroom mechanism, or next-step decision about Trial-access debate. It cannot by itself prove causation, establish a real clinical diagnosis, or justify action outside this classroom task.
A terminal patient qualifies for a right-to-try request, but the drug maker still refuses. Is the company breaking the law, and give the reason.
Write an answer and pick a confidence to unlock the key.
Fast retrieval with instant answers, not the commit-then-reveal check above. Try each from memory first: write what you remember about the earlier units, then check yourself here.
Go further and get help▸
What today's skills lead to. These are real health-science careers this course builds toward. Tap one to see, on the US Department of Labor's O*NET site, what the job actually involves, what it pays, and how fast it is growing.
Record a two-minute voice memo arguing your trial-access stance from one stakeholder role, then post one written rebuttal to a classmate's posted claim in the course shell discussion.
NCI: Clinical Trials BasicsThen submit your Exit ticket. Turn this in at the drop folder with your district Microsoft sign-in, or hand it to Mr. Mendoza in class. Both count as submitted. Doing the activity in myPLTW does not.
Class still runs. Complete the online activity above (it's self-guided). Need the concept taught without a teacher? Use this authoritative explainer:
National Cancer Institute: Types of cancer treatmentYou've passed Unit 2, so the optional extra-credit track is open. Complete reserved-unit work from home, including virtual labs, for extra credit. Each item shows its correct submission route.
Open the extra-credit track- CompleteEvery required part of the artifact is present, nothing left blank.
- AccurateThe science and the data are correct and match the evidence.
- Scientific reasoningYou explain your claim with evidence and reasoning (CER), not just an answer.
- Professional communicationClear, organized, labeled, and written the way a clinician or scientist would.
- SubmittedTurned in the right way, on the class site or handed to Mr. Mendoza in class, and confirmed. Not in Schoology: that is where the report-card grade appears later.